文献速递脊柱关节炎

早期银屑病关节炎的合并症:来自银屑病关节炎代谢紊乱队列研究的数据

Comorbidities in Early Psoriatic Arthritis: Data From the Metabolic Disturbances in Psoriatic Arthritis Cohort Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-01-15

该观察性纵向多中心队列研究比较了67例未治疗早期银屑病关节炎(ePsA)患者与61名性别年龄匹配健康对照的合并症和心血管危险因素,发现ePsA患者心血管危险因素比例更高(82.1% vs 62.3%),多种合并症和多种心血管危险因素风险也更高;随访1年疾病活动改善但合并症比例无变化。

要点

  • 早期银屑病关节炎患者心血管危险因素比例高于健康对照(82.1% vs 62.3%)。
  • 早期银屑病关节炎患者多种合并症风险(OR 1.9)和多种心血管危险因素风险(OR 2.1)均高于对照。
  • 随访1年疾病活动评分改善,但合并症和心血管危险因素比例未增加也未下降。

核心结论

  • 数据显示银屑病关节炎患者在疾病早期即存在较高的合并症和心血管负担,提示这些合并症并非仅由长期疾病和慢性系统性炎症所致。

研究设计与样本

  • 观察性纵向多中心队列研究,纳入67例未治疗早期银屑病关节炎患者和61名性别年龄匹配健康对照,比较临床人口学特征、心血管危险因素和合并症,并在患者中于1年随访后重新评估合并症。

主要发现

  • ePsA患者与健康对照的合并症总体比例相似。
  • ePsA患者基线心血管危险因素比例为82.1%,健康志愿者为62.3%(OR 1.6,95%CI 1.14-2.0)。
  • ePsA患者有≥2种合并症的OR为1.9(95%CI 1.2-3.0),有≥2种心血管危险因素的OR为2.1(95%CI 1.3-3.2),均高于对照。
  • ePsA患者的合并症或心血管危险因素不受皮肤银屑病病程影响。
  • 血脂异常是银屑病关节炎队列中最常见的合并症(64.2% vs 对照39.3%;OR 1.7,95%CI 1.2-2.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to investigate the prevalence of comorbidities and cardiovascular (CV) risk factors (RFs) in treatment-naive patients with early psoriatic arthritis (ePsA) and to identify factors that contribute to metabolic burden in ePsA. METHODS: This was an observational longitudinal multicenter cohort study. Clinical and demographic characteristics, CV RFs, and comorbidities were compared in patients newly diagnosed with psoriatic arthritis (PsA) and sex- and age-matched controls. In patients with PsA, comorbidities were reevaluated after one year's follow-up because the disease activity changed. RESULTS: Sixty-seven patients with ePsA and 61 healthy volunteers were included. The rate of comorbidities was similar in patients with ePsA and in healthy controls; 82.1% of patients with ePsA had CV RFs at baseline as compared with 62.3% of healthy volunteers (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.14-2.0). Patients with ePsA had higher odds of having multiple (two or more) comorbidities (OR 1.9, 95% CI 1.2-3.0) and multiple CV RFs (OR 2.1, 95% CI 1.3-3.2) than the controls. Comorbidities or CV RFs in patients with ePsA were not influenced by duration of skin psoriasis. Dyslipidemia was the most prevalent comorbidity in the PsA cohort (64.2% vs 39.3% in controls; OR 1.7, 95% CI 1.2-2.5). Patients with ePsA had, on average, above normal body mass index (mean ± SD 28.82 ± 4.5) and a higher rate of obesity (40.3% vs 18.3% in controls; OR 1.9, 95% CI 1.1-3.2). After 1 year, although disease activity scores improved, the proportion of patients with comorbidities and CV RFs did not increase or drop. CONCLUSION: Our data imply that patients with PsA already have higher comorbidities and CV burden at early stages of the disease, suggesting that these are not only a consequence of long-lasting disease and chronic systemic inflammation.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Ishchenko A, Pazmino S, Neerinckx B, et al. Comorbidities in Early Psoriatic Arthritis: Data From the Metabolic Disturbances in Psoriatic Arthritis Cohort Study. Arthritis Care Res (Hoboken). 2024. PMID: 37667975. doi:10.1002/acr.25230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。